According to Zhitong Finance App News, Shiyao Group (01093.HK) announced that at the 2026 World Lung Cancer Conference (WCLC) hosted by the International Association for Lung Cancer Research (IASLC), the group announced phase I/II clinical data on SYS6010 combined with enranzubimab for the treatment of advanced driver gene negative non-small cell lung cancer (NSCLC) without systematic treatment in the form of an oral report.
智通财经·09/14/2026 09:41:10
语音播报
According to Zhitong Finance App News, Shiyao Group (01093.HK) announced that at the 2026 World Lung Cancer Conference (WCLC) hosted by the International Association for Lung Cancer Research (IASLC), the group announced phase I/II clinical data on SYS6010 combined with enranzubimab for the treatment of advanced driver gene negative non-small cell lung cancer (NSCLC) without systematic treatment in the form of an oral report.